Leading the Way in Life Science Technologies

GEN Exclusives

More »
Diagnostics - Related Content
  • Corporate Profile: The Rise of Theragnostics
    Radiopharmaceutical Company’s Compounds Combine Therapeutic and Diagnostic Capabilities
  • Feature Articles: Special Report: Microarray Not Fade Away
    Yes, many are attracted to next-generation sequencing, but loyalty to chip-based phenotyping has its rewards, particularly in screens of large sample sets.
  • Feature Articles: GEN Roundup on Flow Cytometry
    An expert panel sorts through reagent, fluorophore, detection channel, and optical system choices to tell you what counts in different applications.
  • Feature Articles: Immunoassays Expand Range of Applications
    Portable and user-friendly assays can be powerful and sophisticated, too, detecting transmembrane proteins and other complex epitopes.
  • Feature Articles: Genomic Singularity Is Near
    Once we’ve uploaded our genomes and the net is abuzz with our biosensor data, virtual doctors and clinics could become very real.
  • Insight & Intelligence™
  • More »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »